• SPX
  • $5,780.05
  • -0.21 %
  • -$11.99
  • DJI
  • $42,454.12
  • -0.14 %
  • -$57.88
  • N225
  • $39,549.27
  • 0.43 %
  • $168.45
  • FTSE
  • $8,237.73
  • -0.07 %
  • -$6.01
  • IXIC
  • $18,282.05
  • -0.05 %
  • -$9.57
Cara Therapeutics, Inc. (CARA) Stock Price, News & Analysis

Cara Therapeutics, Inc. (CARA) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.26

-$0

(-0.62%)

Day's range
$0.25
Day's range
$0.26
50-day range
$0.245
Day's range
$0.372
  • Country: US
  • ISIN: US1407551092
52 wk range
$0.24
Day's range
$1.65
  • CEO: Mr. Christopher A. Posner
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -17.85
  • Piotroski Score 2.00
  • Grade Hold
  • Symbol (CARA)
  • Company Cara Therapeutics, Inc.
  • Price $0.26
  • Changes Percentage (-0.62%)
  • Change -$0
  • Day Low $0.25
  • Day High $0.26
  • Year High $1.65

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/10/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $13.50
  • High Stock Price Target $30.00
  • Low Stock Price Target $1.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.26
  • Trailing P/E Ratio -0.28
  • Forward P/E Ratio -0.28
  • P/E Growth -0.28
  • Net Income $-118,513,000

Income Statement

Quarterly

Annual

Latest News of CARA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.